These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 31887451)

  • 21. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.
    Younossi ZM; Gramlich T; Liu YC; Matteoni C; Petrelli M; Goldblum J; Rybicki L; McCullough AJ
    Mod Pathol; 1998 Jun; 11(6):560-5. PubMed ID: 9647594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Kleiner DE; Brunt EM; Van Natta M; Behling C; Contos MJ; Cummings OW; Ferrell LD; Liu YC; Torbenson MS; Unalp-Arida A; Yeh M; McCullough AJ; Sanyal AJ;
    Hepatology; 2005 Jun; 41(6):1313-21. PubMed ID: 15915461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
    Kleiner DE; Makhlouf HR
    Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histopathology, grading and staging of nonalcoholic fatty liver disease.
    Kleiner DE
    Minerva Gastroenterol Dietol; 2018 Mar; 64(1):28-38. PubMed ID: 28948754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
    Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
    PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis.
    Sugimoto K; Moriyasu F; Oshiro H; Takeuchi H; Abe M; Yoshimasu Y; Kasai Y; Sakamaki K; Hara T; Itoi T
    Radiology; 2020 Sep; 296(3):532-540. PubMed ID: 32573385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
    Lee J; Westphal M; Vali Y; Boursier J; Petta S; Ostroff R; Alexander L; Chen Y; Fournier C; Geier A; Francque S; Wonders K; Tiniakos D; Bedossa P; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison S; Cobbold J; Holleboom AG; Yki-Järvinen H; Crespo J; Ekstedt M; Aithal GP; Bugianesi E; Romero-Gomez M; Torstenson R; Karsdal M; Yunis C; Schattenberg JM; Schuppan D; Ratziu V; Brass C; Duffin K; Zwinderman K; Pavlides M; Anstee QM; Bossuyt PM;
    Hepatology; 2023 Jul; 78(1):258-271. PubMed ID: 36994719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
    Pai RK; Jairath V; Hogan M; Zou G; Adeyi OA; Anstee QM; Aqel BA; Behling C; Carey EJ; Clouston AD; Corey K; Feagan BG; Kleiner DE; Ma C; McFarlane SC; Noureddin M; Ratziu V; Valasek MA; Younossi ZM; Harrison SA; Loomba R
    Hepatology; 2022 Oct; 76(4):1150-1163. PubMed ID: 35332569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
    Bedossa P; Poitou C; Veyrie N; Bouillot JL; Basdevant A; Paradis V; Tordjman J; Clement K
    Hepatology; 2012 Nov; 56(5):1751-9. PubMed ID: 22707395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH.
    De Rudder M; Bouzin C; Nachit M; Louvegny H; Vande Velde G; Julé Y; Leclercq IA
    Lab Invest; 2020 Jan; 100(1):147-160. PubMed ID: 31506634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.